In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus

Sang-Hun Oh 1,†, Hee-Soo Park 2,†, Jun-Hyung Lee 1, Sung-Yun Baek 3, Sang-Eun Chae 3, Kyuman Oh 3, Young Lag Cho 3 and Jin-Hwan Kwak 1,*

1 School of Life Science, Handong Global University, Pohang 37554, Korea; osh8755@naver.com (S.-H.O.); gohyo9@gmail.com (J.-H.L.)
2 Institute of Agricultural Science & Technology, School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Korea; phsoo97@knu.ac.kr
3 LegoChem BioSci. Inc., Daejeon 34302, Korea; bsy@legochembio.com (S.-Y.B.); sangeun@legochembio.com (S.-E.C.); kyuman@legochembio.com (K.O.); young@legochembio.com (Y.L.C.)
* Correspondence: jhkawk@handong.edu; Tel.: +82-54-260-1353; Fax: +82-54-260-1925
† These authors contributed equally to this work.

Received: 10 November 2017; Accepted: 28 November 2017; Published: 29 November 2017

Abstract: LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.

Keywords: LCB01-0699; LCB01-0648; oxazolidinone; in vivo activity; skin infection

1. Introduction

Multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), beta-lactam-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci (VRE), are widespread around the world, and are a major concern for nosocomial infections with high morbidity and mortality [1,2]. Although a rapid increase in resistant bacteria is occurring, the development of novel antibiotics for use in the treatment of infectious diseases is limited [3]. Therefore, developing novel antibiotics for treatment of these infectious diseases caused by multidrug resistant Gram-positive bac teria is necessary [4,5].

Oxazolidinones are a new class of synthetic antibiotics that bind to 23S ribosomal RNA, a component of the 50S subunit of the bacterial ribosome, thereby inhibiting the initiation of protein synthesis [6,7]. Because oxazolidinones have potent antimicrobial activities against Gram-positive bacteria, oxazolidinones have been used for the treatment of soft- and skin-tissue infectious diseases caused by multidrug-resistant Gram positive cocci [8,9]. Linezolid is the first oxazolidinone antibiotic approved by the United States Food and Drug Administration (USFDA) in 2000 [10]. While Linezolid has been used for infectious diseases, several Linezolid-resistant staphylococci have been reported globally [11]. To overcome Linezolid-resistant S. aureus (LRSA), development of second-generation oxazolidinones with potent activities against Linezolid-resistant S. aureus or other multi-drug resistant Gram-positive cocci is required. Recently, Sivextro (tedizolid phosphate), a second-generation...
oxazolidinone, was approved by the USFDA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain Gram-positive bacteria [12].

Previously, we reported on the antibacterial activities of a novel oxazolidinones LCB01-0648, containing cyclic amidrazone [13]. LCB01-0648 showed potent antibacterial activities against clinically isolated Gram-positive cocci, suggesting that LCB01-0648 could be a good antibiotic candidate for treatment of infectious diseases caused by Gram-positive cocci [13]. While LCB01-0648 has potent antibacterial activities against multi-drug Gram-positive cocci in vitro, the in vivo activity of LCB01-0648 had not yet been examined. To examine the in vivo activity of LCB01-0648, LCB01-0699, a prodrug of LCB01-0648 was used (Figure 1). First, pharmacokinetic results demonstrated that most LCB01-0699 converts to the active form LCB01-0648 in the rat model. Two infection models, including systemic- and skin-infection models, were used for examination of the in vivo efficacy of LCB01-0699, and found that LCB01-0699 was similarly active to or more active than Linezolid against methicillin-susceptible and -resistant S. aureus.

![Figure 1. Chemical structures of LCB01-0648 and LCB01-0699.](image)

2. Results

Previously, we reported that LCB01-0648 had potent in vitro activity and minimal safety issues [13]. To examine whether LCB01-0699 was really converted to LCB01-0648 in vivo, a pharmacokinetic study was conducted in a rat model system. A single dose of LCB01-0699 was administrated as a bolus injection through the tail vein, and serum samples were analyzed by high-performance liquid chromatography (HPLC) assay. As shown in Figure 2, most of the LCB01-0699 was converted to LCB01-0648 rapidly. The C\text{max} (peak concentration), T\text{max} (time required to reach maximum) and AUC\text{last} (area under the concentration-time curve from time zero to the last sampling time) of LCB01-0699 were found to be 42.9 mg·h L\text{−1}, 0.03 h and 5.08 mg·h L\text{−1}, respectively. The C\text{max}, T\text{max} and AUC\text{last} of LCB01-0648 were found to be 41.1 mg·h L\text{−1}, 0.07 h and 85.0 mg·h L\text{−1}, respectively (Table 1). These results demonstrate that most of the prodrug LCB01-0699 converted to LCB01-0648.

![Figure 2. (A) Proposed biotransformation of LCB01-0699; (B) Average (±SD) plasma concentration of LCB01-0699 and their metabolites versus time plots of 24 subjects after administration of 15 mg/kg LCB01-0699.](image)
Table 1. Pharmacokinetic parameters of LCB01-0699 and metabolites in rat plasma after a single 15 mg/kg intravenous (i.v.) injection of LCB01-0699 (n = 3).

| Compounds | Parameters | LCB01-0699 (15 mg/kg) |
|-----------|------------|-----------------------|
| LCB01-0699 | $T_{\text{max}}$ (h) $^a$ | 0.03 ± 0.00 |
|           | $C_{\text{max}}$ (mg/L) $^b$ | 42.9 ± 4.21 |
|           | $AUC_{\text{last}}$ (mg·h/L) $^c$ | 5.08 ± 0.68 |
| LCB01-0648 | $T_{\text{max}}$ (h) | 0.07 ± 0.03 |
|           | $C_{\text{max}}$ (mg/L) | 41.1 ± 8.09 |
|           | $AUC_{\text{last}}$ (mg·h/L) | 85.0 ± 46.4 |
| M1        | $T_{\text{max}}$ (h) | 1.00 ± 0.00 |
|           | $C_{\text{max}}$ (mg/L) | 2.51 ± 0.98 |
|           | $AUC_{\text{last}}$ (mg·h/L) | 9.13 ± 4.23 |
| M2        | $T_{\text{max}}$ (h) | 4.00 ± 0.00 |
|           | $C_{\text{max}}$ (mg/L) | 0.72 ± 0.27 |
|           | $AUC_{\text{last}}$ (mg·h/L) | 8.45 ± 2.42 |
| Sum       | $C_{\text{max}}$ (mg/L) | 87.2 |
|           | $AUC_{\text{last}}$ (mg·h/L) | 107.7 |

$^a$ $T_{\text{max}}$: Time required to reach maximum; $^b$ $C_{\text{max}}$: peak concentration; $^c$ $AUC_{\text{last}}$: Area under the concentration-time curve from time zero to the last sampling time.

To examine the in vivo activities of LCB01-0699, we first used a systemic-infection mouse model. The median effective dose needed to protect 50% of the mice (ED$_{50}$) of LCB01-0699 were 6.20 and 2.23 mg/kg of body weight against S. aureus Giorgio (methicillin-susceptible S. aureus) and S. aureus P125 (methicillin-resistant S. aureus), respectively, when orally administered (p.o.) (Table 2). Against infection caused by methicillin-susceptible and -resistant S. aureus, The median effective dose needed to protect 50% of the mice (ED$_{50}$s) of LCB01-0699 were 5.51 and 2.73 mg/kg of body weight, respectively, when LCB01-0699 was administered by the subcutaneous route (s.c.). These results demonstrate that LCB01-0699 is more potent than Linezolid against methicillin-susceptible and -resistant S. aureus.

Table 2. In vivo activity of LCB01-0699 against S. aureus in a mouse model of systemic infection.

| Microorganism Inoculum $^a$ (CFU/Mouse) $^b$ | Antimicrobial Agent $^c$ | MIC $^d$ (mg/L) | ED$_{50}$ (mg/kg) $^e$ (95% Confidence Limits) |
|-----------------------------------------------|------------------------|-----------------|-----------------------------------------------|
| S. aureus Giorgio (methicillin-susceptible S. aureus) ($5 \times 10^7$) | LCB01-0699 | 0.5 | 6.20 (3.58–10.65) |
|                                              | Linezolid | 2   | 7.07 (4.07–12.29) |
| S. aureus P125 (methicillin-resistant S. aureus) ($5 \times 10^7$) | LCB01-0699 | 0.5 | 2.33 (0.94–5.28) |
|                                              | Linezolid | 2   | 7.07 (4.07–12.29) |

$^a$ Bacterial strains were suspended in 0.9% saline solution containing 5% mucin solution; $^b$ CFU: colony-forming units; $^c$ Antibiotics at various dose regimens were administered subcutaneously at 1 and 4 h after the bacterial infection; $^d$ MIC: Minimum inhibitory concentration; $^e$ ED$_{50}$: median effective dose needed to protect 50% of the mice; $^f$ p.o.: orally administered; $^g$ s.c.: the subcutaneous route.

We then examined the in vivo effect of LCB01-0699 by using a soft-tissue infection model caused by S. aureus Giorgio (methicillin-susceptible S. aureus) and S. aureus P125 (methicillin-resistant S. aureus). As shown Figure 3, LCB01-0699 showed reduced bacterial count in a dose-dependent manner in air-pouch fluid. At a concentration of 20 mg/kg of body weight, the antibacterial activity of LCB01-0699 was better than that of Linezolid in both methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 has potent activity in soft-tissue infection model.
Tedizolid uses a prodrug form—Tedizolid phosphate (TR-701), a second-generation oxazolidinone, was developed for the treatment of skin-infection diseases caused by Gram-positive cocci including S. aureus [8]. Until now, two agents, Linezolid 

\[
\text{Figure 3. In vivo activities of LCB01-0699 and Linezolid against (A) S. aureus Giorgio (methicillin-susceptible S. aureus) and (B) S. aureus P125 (methicillin-resistant S. aureus) in mouse model of skin infection. Each bar represents mean ± SD. CFU: colony-forming units.}
\]

Because myelosuppression is associated with Linezolid [14], we conducted a myelosuppression assay. Similar to LCB01-0648, LCB01-0699 was not able to cause any change of reticulocyte count (RTC, %) (Figure 4), suggesting that LCB01-0699 may not be associated with myelosuppression.

\[
\text{Figure 4. Myelosuppression toxicity of LCB01-0699. Each bar represents mean ± SD.}
\]

3. Discussion

Oxazolidinones are a novel group of antibiotics that have potent activities against Gram-positive pathogens [8]. Until now, two agents, Linezolid and tedizolid, have been approved in USFDA. Tedizolid phosphate (TR-701), a second-generation oxazolidinone, was developed for the treatment of skin-infection diseases caused by Gram-positive cocci including S. aureus [12]. Unlike Linezolid, Tedizolid uses a prodrug form—Tedizolid phosphate—for treatment, and this prodrug is rapidly converted by phosphatases to tedizolid in humans.
Previously, we demonstrated that LCB01-0648, a novel oxazolidinone agent, has potent in vitro antibacterial activities of LCB01-0648 against Gram-positive cocci [15]. In this study, we further examined the in vivo activity of LCB01-0648, the prodrug form of LCB01-0699, the LCB01-0648 phosphate form, is quickly converted to the active form LCB01-0648 in rat plasma after intravenous injection. LCB01-0699 was more active than Linezolid against both methicillin-susceptible and -resistant S. aureus strains in systemic and skin mouse models, suggesting that LCB01-0699 could be a good oxazolidinone agent for treatment of skin infection caused by methicillin-resistant S. aureus. Because LCB01-0699 showed less bone marrow toxicity (Figure 4), LCB01-0699 is considered a potential antibacterial candidate, with high activities and low toxicity. While our previous study provided in vitro activities of LCB01-0648 against Linezolid-resistant S. aureus or other Gram-positive cocci [13], we did not provide in vivo activity of LCB01-0699 against Linezolid-resistant S. aureus or other Gram-positive cocci. Therefore, further in vivo analyses should be carried out to better understand the antibacterial activity of LCB01-0699 against multi-drug resistant Gram-positive cocci, including Linezolid-resistant S. aureus.

4. Materials and Methods

4.1. Antimicrobial Agents and Bacterial Strains

LCB01-0699 and Linezolid were synthesized at the LegoChem Bioscience, Inc., Daejeon, Korea. For in vivo experiments, methicillin-susceptible S. aureus Giorgio, obtained from LG Chem, Ltd., Seoul, Korea, and methicillin-resistant S. aureus strain P125 were previously selected through the screening of clinical isolates in the previous study [16].

4.2. Systemic Infection Model

S. aureus Giorgio or P125 were cultured in Mueller-Hinton agar (MHA, Difco, Sparks, MD, USA) medium at 37 °C for 18 h and were suspended in 5% gastric mucin (Sigma-Aldrich Co., St. Louis, MO, USA). Four-week-old male mice weighing 19 to 21 g, with each group being 5 mice in a single cage, were injected intraperitoneally with the bacterial suspension corresponding to an inoculum range of 5 to 10 times the minimum lethal dose (MLD) of bacteria. Four dose levels were used for each antibiotic, depending on the Minimum inhibitory concentration (MIC) of the compound. LCB01-0699 and Linezolid at various dose regimens were administered orally (p.o.) or subcutaneously (s.c.), twice at 1 and 4 h post infection. Mortality was recorded for 7 days, and the median effective dose needed to protect 50% of the mice (ED$_{50}$) was calculated by the Probit method.

4.3. Soft Tissue Infection Model

Four-week-old female IcrTacSam (ICR) mice (18 to 23 g) were used in groups of three for each dose. After 24 h, challenge bacterial strains with 5% mucin (Sigma-Aldrich Co., St. Louis, MO, USA) were infected into the air pouches. LCB01-0699 and Linezolid were orally administered (p.o.) at 0 h after the bacterial infection. After 24 h, 3 mL of saline was injected into the pouch, and the fluid from the pouch was removed immediately. The fluid from the pouch was serial diluted with saline and were then plated on Mueller-Hinton agar plates to count the number of residual bacteria.

4.4. Mice and Ethics Statement

For in vivo experiments, male or female IcrTacSam (ICR) mice were purchased from the Daehan Bio Link Co., Ltd., Eumseong, Korea. All animals were maintained in the specific-pathogen-free (SPF) facility, where the cages in the animal room were maintained at 22 ± 2 °C temperature and 55 ± 1.0% relative humidity. The facilities were adjusted day and night at 12-h intervals (9 a.m. and 9 p.m.). Before the experiment, the mice were separated into cages by weight. All animal experiments were conducted in accordance with the ethical guidelines of the Ethics Review Committee for Animal Experimentation at Handong Global University (Pohang, Korea) (protocol #HGU-2010-04 and #HGU-20151022-003).
4.5. Pharmacokinetic Analysis

A total of 3 male Sprague Dawley (SD) rats (Orient Bio Inc., Seongnam, Korea weighing 280–311 g) were used in this study. Animals were fasted overnight before and for 4 h after dosing. The animal room was controlled for illumination (12 h light/dark cycle), temperature (19–25 °C) and relative humidity (>40%). The phosphate prodrug LCB01-0699 (7.5 mg/mL) was administered as an intravenous bolus dose at 15 mg/kg via tail vein. Following intravenous administration, blood samples (0.5 mL) were collected from the jugular vein prior to dosing, and at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 10 and 24 h post-dose. Blood samples were collected in tubes containing sodium-heparin, and centrifuged at 14,000 rpm for 5 min at 4 °C to separate plasma from the blood samples. Following centrifugation, 100 µL aliquots of plasma were stored at −70 °C until high-performance liquid chromatography with tandem mass spectrometry (HPLC/MS/MS) analysis. The plasma concentrations of LCB01-0699, LCB01-0648 and metabolites (M1, M2) were determined by protein precipitation, and by using the high-performance liquid chromatography with tandem mass spectrometry (HPLC/MS/MS) method. The pharmacokinetic parameters were determined for LCB01-0648 and metabolites from individual plasma concentration-time data using the linear log trapezoidal calculation method. A non-compartmental analysis of Phoenix WinNonlin® Professional 6.4 (Certara USA, Inc., Princeton, NJ, USA) was used to calculate parameters.

4.6. Myelosuppression Assay

A myelosuppression assay was carried out as previously described [13]. Briefly, female C3H/HeJ (C3H) mice (6–7 weeks) were purchased from Orient Bio. Charles River Laboratories (Seongnam, Korea). LCB01-0699 (20 or 50 mg/kg) was orally administered (p.o.) once daily for 4 days using a sonde attached to disposable syringes. Mice were sacrificed by ether 4 days after treatment. All animals had been fasted for approximately 16 h prior to sacrifice. Blood samples were collected from the vena cava and were put into a tube containing EDTA (Ethylenediaminetetraacetic acid) (Becton Dickinson, Sparks, MD, USA). Samples were analyzed by Biotoxtech Co. Ltd. (Cheongju, Korea).

5. Conclusions

Overall, our in vitro and in vivo results propose that LCB01-0699, a prodrug form of LCB01-0648, could be a promising compound for treatment of skin infectious disease caused by multi-drug resistant Gram-positive pathogens.

Acknowledgments: This research was supported by LegoChem BioSci Inc.

Author Contributions: The author contributions are as follows: S.-H.O., J.-H.L., S.-Y.B., S.-E.C. and K.O. designed and performed the experiments; S.-H.O. and H.-S.P. analyzed the data; S.-H.O., H.-S.P. and J.-H.K. wrote the paper; and J.-H.K. and Y.L.C. supervised the study and helped interpret the results.

Conflicts of Interest: The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References

1. Levy, S.B.; Marshall, B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat. Med. 2004, 10, S122–S129. [CrossRef] [PubMed]
2. Ventola, C.L. The antibiotic resistance crisis: Part 1: Causes and threats. Pharm. Ther. 2015, 40, 277–283.
3. Cynamon, M.H.; Klemens, S.P.; Sharpe, C.A.; Chase, S. Activities of several novel oxazolidinones against mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 1999, 43, 1189–1191. [PubMed]
4. Brown, E.D.; Wright, G.D. Antibacterial drug discovery in the resistance era. Nature 2016, 529, 336–343. [CrossRef] [PubMed]
5. Draenert, R.; Seybold, U.; Grutzner, E.; Bogner, J.R. Novel antibiotics: Are we still in the pre-post-antibiotic era? Infection 2015, 43, 145–151. [CrossRef] [PubMed]
6. Bozdogan, B.; Appelbaum, P.C. Oxazolidinones: Activity, mode of action, and mechanism of resistance. *Int. J. Antimicrob. Agents* 2004, 23, 113–119. [CrossRef] [PubMed]
7. Barbachyn, M.R.; Ford, C.W. Oxazolidinone structure-activity relationships leading to linezolid. *Angew. Chem. Int. Ed. Engl.* 2003, 42, 2010–2023. [CrossRef] [PubMed]
8. Diekema, D.J.; Jones, R.N. Oxazolidinone antibiotics. *Lancet* 2001, 358, 1975–1982. [CrossRef]
9. Pandit, N.; Singla, R.K.; Shrivastava, B. Current updates on oxazolidinone and its significance. *Int. J. Med. Chem.* 2012, 2012, 159285. [CrossRef] [PubMed]
10. Moellering, R.C. Linezolid: The first oxazolidinone antimicrobial. *Ann. Intern. Med.* 2003, 138, 135–142. [CrossRef] [PubMed]
11. Gu, B.; Kelesidis, T.; Tsiodras, S.; Hindler, J.; Humphries, R.M. The emerging problem of linezolid-resistant staphylococcus. *J. Antimicrob. Chemother.* 2013, 68, 4–11. [CrossRef] [PubMed]
12. Wong, E.; Rab, S. Tedizolid phosphate (sivextro): A second-generation oxazolidinone to treat acute bacterial skin and skin structure infections. *Pharm. Ther.* 2014, 39, 555–579.
13. Oh, S.H.; Kim, J.; Baek, S.Y.; Chae, S.E.; Park, H.S.; Cho, Y.L.; Kwak, J.H. In vitro activities of LCB 01–0648, a novel oxazolidinone, against gram-positive bacteria. *Molecules* 2017, 22, 394. [CrossRef] [PubMed]
14. Green, S.L.; Maddox, J.C.; Huttenbach, E.D. Linezolid and reversible myelosuppression. *JAMA* 2001, 285, 1291. [CrossRef] [PubMed]
15. Locke, J.B.; Hilgers, M.; Shaw, K.J. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. *Antimicrob. Agents Chemother.* 2009, 53, 5275–5278. [CrossRef] [PubMed]
16. Park, H.S.; Kim, H.J.; Seol, M.J.; Choi, D.R.; Choi, E.C.; Kwak, J.H. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. *Antimicrob. Agents Chemother.* 2006, 50, 2261–2264. [CrossRef] [PubMed]

**Sample Availability:** Samples of the compounds are not available from the authors.